Memory Pharmaceuticals Drug Fails Trial; Shares Plunge Pre-Market MONTVALE, N.J., March 5 -- Memory Pharmaceuticals Corp. today announced top-line data from the Phase 2a study of MEM 1003 in acute ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results